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Abstract
Recent biotechnological advances have permitted the manipulation of genetic sequences to treat several diseases in a process 
called gene therapy. However, the advance of gene therapy has opened the door to the possibility of using genetic manipula-
tion (GM) to enhance athletic performance. In such ‘gene doping’, exogenous genetic sequences are inserted into a specific 
tissue, altering cellular gene activity or leading to the expression of a protein product. The exogenous genes most likely to 
be utilized for gene doping include erythropoietin (EPO), vascular endothelial growth factor (VEGF), insulin-like growth factor 
type 1 (IGF-1), myostatin antagonists, and endorphin. However, many other genes could also be used, such as those involved 
in glucose metabolic pathways. Because gene doping would be very difficult to detect, it is inherently very attractive for those 
involved in sports who are prepared to cheat. Moreover, the field of gene therapy is constantly and rapidly progressing, and 
this is likely to generate many new possibilities for gene doping. Thus, as part of the general fight against all forms of doping, 
it will be necessary to develop and continually improve means of detecting exogenous gene sequences (or their products) in 
athletes. Nevertheless, some bioethicists have argued for a liberal approach to gene doping.
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In the domain of genetics, scientific knowledge has 
made many remarkable advances in recent years. In the 
last decade, the publication of the human genome (1,2), 
together with much molecular information existing at the 
time, has permitted genetic manipulation (GM) techniques 
to be used in the treatment of various diseases. In the past, 
doping and cheating in sports were enabled by advances in 
pharmacology and physiology. Now, advances in molecular 
genetics have given rise to the potential to improve various 
non-medical human features including sports performance 
by the use of GM technology (3,4).
Gene expression is regulated primarily by two main 
mechanisms: a) changes in DNA structure and b) direct 
control over the processes of transcription and translation. 
The first includes epigenetic modifications and mutations. 
Through epigenetics, the degree of gene transcription is 
altered, without causing changes in DNA sequence (5). Also 
of importance, mutations promote changes in the nucle-
otide sequence of the gene and can derail the process of 
transcription or generate a new product, different from the 
original (6). The second mechanism consists of repressor 
and inductor molecules, transcription factors, enhancers 
and post-transcriptional modifiers (7). Thus, some changes 
in the regulatory process may result in an increased or 
decreased concentration of gene product.
The World Anti-Doping Agency (WADA) considers gene 
doping as the use of pharmacological or biological agents 
that alter gene expression, or the transfer of cells or genetic 
elements (DNA and RNA) (8). As explained by Sharp (9), 
some changes in gene expression are potentially able to 
increase sports performance in a number of ways (Figure 1). 
Such expression changes have the potential to up-regulate 
cellular functions in a wide variety of organs and tissues, 
leading to potential performance benefits. Examples include 
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increased erythrocyte production and enhanced oxygen 
transfer via bone marrow targeting (10); liver targeting to 
increase Cori-cycle lactate-removing kinetics and energetic 
metabolism (11), erythropoietin (EPO) synthesis via kidney 
targeting (12), targeting of the myocardium to enhance 
cardiac output, and skeletal muscle targeting to influence 
fiber-type quality, percentage, sarcomere structure, mito-
chondrial number, glycolytic/glycogenesis enzymes, and 
muscle capillary numbers (13,14). It might even be pos-
sible to target neurologic areas in order to increase pain 
tolerance (15). 
The rapid improvement of biotechnology inadvertently 
supplied fuel to drive the development of doping in all its 
modern forms. From recombinant protein production in 
GM microorganisms to gene doping, detection of athletes 
who have benefitted from such abuse remains a major 
technological challenge (16). Moreover, the new oppor-
tunities generated by recent scientific advances require 
bioethical analysis. What, if any, limits should be placed 
on the use of science to promote athletic performance? 
Should sportspeople be permitted to use gene therapy 
to treat disorders even if this results in improved perfor-
mance? Does GM technology threaten to undermine the 
very spirit of sport? In this review article, we will provide 
a current overview of gene doping possibilities, including 
their development and detection techniques. 
Candidate genes for use in gene doping
Erythropoietin: increase in energy production by 
aerobic metabolism 
In adults, EPO is produced mostly by interstitial cells 
Figure 1. Targeted tissues and organs for gene doping. Main aims of gene doping to enhance sports 
performance: improvement of pain tolerance (endorphin/enkephalin genes), muscle quality and vascular-
ization (VEGF gene and myostatin antagonists) and erythrocyte number (EPO gene). With more genomic 
understanding, other organs will be targeted in the future, such as heart and kidneys, to increase cardiac 
output and EPO production, respectively. VEGF = vascular epithelial growth factor; EPO = erythropoi-
etin.
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within the kidney, and in small quantities by the liver, where 
fetal synthesis occurs (17). Erythropoiesis is regulated by 
the concentration of circulating oxygen, and thus differs 
in conditions of normal oxygen tension (normoxia) and 
low oxygen tension (hypoxia) (18). The enzymes prolyl 
hydroxylase and asparaginyl hydroxylase are sensors of 
the level of intracellular oxygen. In normoxia, the hypoxia-
inducible transcription factor 1α (HIF-1α) has its proline 
residues 402 and 567 hydroxylated at O2-dependent sites 
of proteosomal degradation. The next step is hydroxylation 
of asparagine residues in the carbon terminal transactiva-
tion domain (C-TAD). These hydroxylations prevent the 
binding of HIF-1α to the nucleotide sequence (A/G) CGTG, 
a regulatory region of the EPO gene. The opposite occurs 
in conditions of hypoxia - the hydroxylations do not occur, 
resulting in binding of HIF-1α to the regulatory region of 
the EPO gene. Thus, in hypoxia the up-regulation of gene 
expression leads to increased levels of intracellular EPO. 
Other transcription factors are also involved in the regulation 
of EPO expression, including HIF-1β, HIF-2α/β and HIF-3α/β 
(19). Following transcription and translation, the resultant 
EPO polypeptide undergoes glycosylation and other post-
translational modifications essential for the establishment 
of proper in vivo function (20).
The hematopoietic system is regulated by three main 
groups of hematopoietic growth factors: a) the colony- 
stimulating factors, b) EPO and thrombopoietin, and c) 
cytokines, mainly interleukins. The erythroid lineage, 
which ultimately yields the erythrocytes, is primarily regu-
lated by signaling performed by EPO (21). Erythropoiesis 
occurs in several steps of cell differentiation: the stem 
cell produces the pluripotent hematopoietic myeloid pro-
genitor, which differentiates into the colony-forming unit 
erythroid (CFU-E). EPO stimulates the proliferation and 
differentiation of this CFU in basophilic, polychromatic and 
orthochromatic erythroblasts, in that order (22). These last 
cells differentiate into reticulocytes. Last, but not least, the 
reticulocytes mature and produce the erythrocytes, cells 
that contain hemoglobin, the key protein involved in gas 
exchange during cell respiration (23). Erythrocytes carry 
oxygen to tissues, where it is used for energy production 
through oxidative phosphorylation. Thus, an increase in 
the number of circulating red blood cells leads to an in-
crease in the body’s ability to supply oxygen to tissues and 
to a concomitantly greater energy production by aerobic 
mechanisms. This is the basic principle for the use of EPO 
in gene doping (24).
Bone marrow contains the early stages of the CFU-E 
progeny. These have a dimerized receptor for EPO, whose 
intracellular portion has a tyrosine kinase-coupled domain, 
called Janus kinase 2 (JAK-2). Binding of EPO to the recep-
tor induces interaction of JAK-2 with the SH2 domain of the 
cytosolic protein STAT 5 (a signal transducer and activator of 
transcription 5). This interaction promotes phosphorylation 
of STAT 5, forming a homodimer of phosphorylated STAT 
5. This facilitates translocation to the nucleus, whereupon 
binding to specific nucleotide sequences takes place, result-
ing in the promotion of transcription of the genes necessary 
for erythropoiesis differentiation (25).
Recombinant human EPO (rhuEPO) is produced on a 
large scale by biotechnological processes and has wide 
application for the treatment of various diseases, such 
as anemia, chronic renal insufficiency, hematological 
malignancies, chemotherapy, and premature birth (26,27). 
Additionally, rhuEPO is used to minimize allogeneic blood 
transfusions after major surgical procedures. Notoriously, 
rhuEPO has also been illicitly used for enhancement of sport 
performance (28).
Fattori et al. (29) analyzed the efficacy of intramuscular 
injection of the EPO gene with the application of electric 
pulses to optimize the process of transduction. The gene was 
electro-injected into mice, rabbits and cynomolgus monkeys 
to test for protein production and biological effects. The 
study concluded that the injected EPO gene yields higher 
levels of circulating EPO and a more pronounced biological 
effect than the endogenous gene in all the species tested, 
thus showing great potential in clinically developable gene 
therapy approaches for EPO delivery.
Vascular endothelial growth factor: increase in 
oxygen supply
Oxygen is vital for the synthesis of ATP by aerobic 
respiration (30). Oxygen, as a small molecule, is able to 
diffuse through the plasma membrane of endothelial cells. 
Therefore, an increased vascular branching promotes a 
more rapid and effective diffusion of oxygen to the tissues 
and a greater availability of it for energy production. Vascular 
endothelial growth factor (VEGF) promotes the branching 
of a preexisting vessel, in a process called angiogenesis 
(31). In gene doping, several copies of the gene coding for 
VEGF would be inserted into the muscle, probably using 
viral vectors. Thus, if successful in athletes, the muscular 
microcirculation would be stimulated and the supply of 
oxygen to the muscles increased (32).
Insulin-like growth factor type 1: increase in muscle 
growth and differentiation
Insulin-like growth factor type 1 (IGF-1) is a 70-amino 
acid polypeptide synthesized primarily in the liver under the 
control of growth hormone (GH) (33). The hypothalamus 
produces two peptides, growth hormone-releasing hormone 
(GHRH) and somatostatin, which control the release of GH 
by the somatotropes of the anterior pituitary. GHRH, sleep, 
intense physical exercise, hypoglycemia, and low levels 
of circulating IGF-1 stimulate the release of GH (34,35). 
However, this is inhibited by somatostatin, hyperglycemia 
and increased blood concentrations of IGF-1. GH acts on 
hepatocytes stimulating production and secretion of IGF-1, 
a growth factor that stimulates the growth and differentiation 
of skeletal muscle tissue and the overall growth of bone 
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tissue (36). The availability of IGF-1 is regulated by binding 
proteins (IGF-BP); IGF-1 is mainly complexed to IGF-BP3. 
Production of IGF-1 also occurs in skeletal muscle, and acts 
in autocrine and paracrine pathways (37).
The main route of intracellular signaling of IGF-1 starts 
with its binding to IGF1R, a receptor formed by dimeriza-
tion of two glycoproteins with the cytoplasmic domains of 
tyrosine kinase (36). The interaction of IGF-1 and its receptor 
induces tyrosine autophosphorylation in the cytoplasmic 
domains of the receptor, triggering an intracellular signal-
ing cascade that promotes the survival and proliferation of 
the muscle cell. IGF-1 also has activities beyond muscular 
effects, including an ability to drive tumor development and 
progression (36,37).
In gene doping, multiple copies of the gene coding for 
IGF-1 might be inserted in skeletal muscle, promoting an 
increase in muscle mass due to hypertrophy of muscle 
cells. This somatic gene insertion could be accomplished 
through the use of two alternative vectors: plasmids or 
viruses. Plasmids represent the least expensive method, 
but also the least efficient. Viral vectors, widely used in 
gene therapy, actively insert the exogenous DNA into the 
genome of the target cell. Viral classes commonly used in 
relevant gene therapy attempts include: a) the adenoviruses, 
with double-stranded DNA, and b) the adeno-associated 
viruses, with single-stranded DNA (9,37).
Myostatin antagonists: increase in muscle 
hypertrophy and hyperplasia
First described by McPherron et al. (38), myostatin, a 
member of the superfamily of transforming growth factor 
(TGF)-β, is a strong negative regulator of skeletal muscle 
growth and differentiation, where its expression predomi-
nates (38,39). The growth of this tissue can be achieved by 
the inhibition of its negative effects using specific antibod-
ies or drugs that bind to myostatin, a principle that has the 
potential to be used in gene doping in order to enhance 
muscle percentage and athletic performance (40). Mosher et 
al. (41) have shown an association between double-muscle 
phenotype and a mutation in the myostatin gene in whippet 
dogs with higher racing performance, thus demonstrating 
the role of this protein in muscle development.
Several substances block the inhibitory activity of 
myostatin, promoting muscle growth and differentiation. 
Important amongst these substances are follistatin and a 
number of follistatin domain-containing proteins; all have 
the ability to bind to myostatin, making it unavailable for its 
natural inhibitory function (42).
Endorphin and enkephalin: increase in pain 
endurance
Pain during or following physical exertion functions as 
a sensory mechanism that serves as an alert to the subject 
that will lead to reduced activity. In evolutionary terms, this 
mechanism presumably developed as a means to avoid 
physical or physiological damage. However, the occurrence 
of pain in an athlete, produced either by injury or metabolic 
changes (for example lactic acid build-up), reduces the 
ability to train and perform. Competitors are trained to psy-
chologically handle pain during intense activities, and may 
consume anti-inflammatory and pain-relieving drugs (43). 
The advantage of a higher resistance to pain has brought 
several candidate genes into focus for potential use in gene 
therapy (for clinical pain) or gene doping. The genes encod-
ing endorphin and enkephalin are prominent contenders in 
this context. The expressed molecules are neuropeptides 
that bind to opioid receptors, promoting analgesic effects 
and, therefore, pain relief. In order to increase the pain 
threshold, copies of these genes might be inserted, with 
expression being targeted to the nervous system (44). This 
promising possibility has been preliminarily studied using 
animal models (45). No such data have been reported in 
humans, suggesting that pain-killing gene therapy will not 
be available soon for clinical use or for gene doping. 
Side effects of gene doping: health risks of 
performance enhancement
Since 2001, when the improvement of athletes’ abilities 
using the principles of gene therapy was discussed for the 
first time, doping has been subject to much discussion, some 
of it polemic, regarding its prohibition. As gene therapy is a 
new form of medicine, and until recently was tested only in 
patients with terminal illnesses, its long-term consequences 
are unknown. Thus, important questions remain to be 
answered about the potential use of GM in the context of 
sport. Perhaps the most fundamental question concerns 
the theoretical possibility that the transgenes used in gene 
doping could inadvertently affect the germ cells, produc-
ing permanent alterations, which could be transmitted to 
future generations (46). At present, there are no definitive 
answers to this question.
Some of the negative effects of gene doping will not be 
specific to GM, but rather to the nature of the gene product 
so expressed. In this regard, the risks of gene doping can 
be analyzed with reference to knowledge (where available) 
on the conventional use of the product concerned. To take 
one example: although there are no descriptions of the 
consequences of gene doping on reproductive parameters 
in vivo and in vitro, studies have shown that EPO stimulates 
steroidogenesis in Leydig cells, triggering an increase in 
testosterone production, leading to a negative feedback on 
the release of reproductive hormones and, consequently, 
reducing spermatogenesis and the spermatic potential, 
which may cause infertility (47). 
By contrast, some studies have shown positive side 
effects of expression products of doping candidate genes, 
such as the reduction of adipogenesis promoted by myosta-
tin antagonists (48) and neuroprotective properties provided 
by EPO-based treatments (49,50). Still, it is necessary to 
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learn more about the complex physiology of each transgene 
product, before it would be safe and acceptable to sanction 
any such use. 
Detection of gene doping: challenges and 
limitations
The detection of gene doping is likely to be difficult, 
although it could be accomplished by a number of avail-
able approaches, involving either direct or indirect methods 
(51). Direct methods involve the detection of recombinant 
proteins or gene insertion vectors (such as viruses or 
plasmids). Indirect methods depend upon the detection of 
signature changes associate with gene doping: for example, 
changes in the immune system following gene transfer, or 
changes in the transcriptome or proteome of a particular 
cell type (Table 1).
In gene therapy, the transgene substitutes for a defective 
gene and thus gene expression will be detected where it 
was previously missing. However, in gene doping, the ex-
pected effect will be an increased concentration of a gene 
product previously expressed at normal levels, thus making 
detection more difficult in the latter case (52). Lasne et al. 
(53) showed some structural differences between endog-
enous and recombinant EPO, via their different isoelectric 
behavior. Another possibility for direct detection is based 
on the use of molecular tests to differentiate the genomic 
DNA from complementary DNA (cDNA). The sequence of 
cDNA does not contain introns, so it can be distinguished 
using techniques such as the polymerase chain reaction 
(PCR) or Southern blotting (54).
The detection of insertion vectors in blood plasma 
presents great difficulties, considering the extremely short 
half-life of circulating plasmids, adenoviruses and adeno-
associated viruses. Thus, the only way to detect the insertion 
vectors in bodily fluids would be through the application of 
molecular tests with relatively short intervals, with the need 
to create a regular testing regime (55).
Indirect methods are based on studies of gene doping 
effects on cells, tissues or the entire organism. This strategy 
includes examining for potential immune responses to gene 
insertion vectors or ‘non-self’ peptides encoded by intro-
duced nucleic acid (52). Recently, the use of transcriptom-
ics, which consists of analysis of tissue mRNA transcripts, 
became a promising potential method to detect gene doping. 
The quantity and composition of a tissue transcriptome is 
highly reflective of its metabolic activity. Some tissues can 
be easily accessed to construct a gene expression pat-
tern. So, it is possible to evaluate some alterations in each 
expression pattern, supporting the development of doping 
detection techniques (56). 
Bioethics of gene doping
In the ancient Olympic Games, athletes competed for 
recognition, eternal fame and an olive branch. Today, such 
motives continue to serve as important reasons for participa-
tion in international competitions; however, they have been 
joined by an additional factor: money. For an athlete, to win 
a medal is a guarantee of lucrative contracts in the future. 
Thus, multiple factors conspire to place pressure upon 
athletes to a hitherto unprecedented degree, generating 
temptations to resort to extreme measures, including con-
ventional doping and, potentially, gene doping (57). 
The main arguments used by the WADA to justify the 
prohibition of gene doping are 2-fold. Uppermost are con-
cerns over potential health risks from the insertion of genes 
or the use of substances that interfere in gene expression. 
Such alterations of gene expression can bring unknown risks 
to the athlete’s health and, should exogenous sequences 
reach the germ line cells, some changes might be transmit-
ted to future generations. A second argument of the WADA 
centers on the issue of fairness. The use of GM to increase 
sports performance is seen as a violation of the sporting 
spirit, giving unfair physical advantages to those who have 
access to the requisite technology (46).
Arguably, there are two ways to analyze the ethical 
status of gene doping (58). The first holds that sports eth-
ics is subservient to medical ethics. So, if the use of gene 
therapy for medicine is permitted, any performance increase 
should be acceptable, essentially as a form of ‘side effect’. 
In this way, a sports physician could prescribe potentially 
performance-enhancing substances - or gene therapy - to 
athletes in order to alleviate a medical condition. However, 
this matter is not straightforward and it is not an easy task 
for a physician to answer the question: how best to treat the 
Table 1. Methods for the detection of gene doping.
Detection Principle Most used techniques
Direct Detection of insertion vectors PCR; Southern blotting
Detection by inserted gene length PCR; Southern blotting
Indirect Quantitative transcriptomics Real-time PCR; microarray
Quantitative proteomics Mass spectroscopy; 2-D electrophoresis
Immune response ELISA; Western blotting
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athlete-patient - more as an athlete or more as a patient? 
Furthermore, some patients might have more interest 
in receiving a treatment that makes them well for sports 
performance, rather than well for life.
The second way to approach sports doping as an ethical 
issue is to consider sports ethics as representing a separate 
entity from medical ethics. In other words, sport is seen as 
a moral practice which, while not requiring a rejection of the 
concepts of medical ethics, depends more on the sporting 
context than on the medical context (59,60).
Viewpoints favorable towards liberalizing the use of 
performance-enhancing agents in sport have been ex-
pressed by some ethicists, albeit a minority thereof (see for 
example, Refs. 58 and 61). The essential argument here 
is that since athletes legitimately strive to improve their 
performance (for example, by use of training methods, nutri-
tion, and psychological conditioning), there are no obvious 
reasons to exclude performance-enhancing agents (e.g., 
anabolic steroids) from the set of methods that may be 
used to enhance athletic performance. While it may seem 
that this would give an unfair advantage to athletes able to 
access these agents, it can be argued that specialist gym 
apparatus, advanced nutrition, and psychological coaching 
are also expensive and thus - like performance-enhancing 
drugs - not available to all athletes. So, it can be argued 
that performance-enhancing drugs should not be singled out 
for prohibition on the basis of a lack of fairness. Similarly, 
health risks are inherent in many forms of sports training; 
thus, banning performance-enhancing agents on grounds 
of safety is arguably inconsistent, as the basis for such 
prohibition implies a similar ban on forms of training, such 
as lifting heavy weights, or practicing gymnastic moves, 
that might conceivably endanger the health of the athlete. 
Logically, any prohibition should be based on an objective 
assessment of risk, which would evaluate drugs and train-
ing methods on an equal basis, as opposed to prohibiting 
simply on the basis of categorizations.
Such pro-enhancement arguments, if accepted with 
respect to conventional performance-enhancing drugs, 
would logically also apply to gene doping (58). At present, 
the risks of human gene therapy are inadequately under-
stood in the context of application to healthy individuals, 
but if a GM method could be shown to carry an acceptably 
low health risk (including any risk of inter-generational 
transmission of introduced gene sequences), then there 
would be no logical grounds for prohibition. Because gene 
therapy is at the cutting edge of medical science, its use 
for performance enhancement would be expensive and 
thus restricted to well-funded athletes, again raising the 
issue of fairness. However, it is an economic rule that 
technologies (e.g., computers, medical devices, etc.) drop 
steeply in price as they come to be used more widely, and 
this rule is very likely to apply to human GM technology. 
Thus, it may be that inexpensive commercial gene therapy 
‘kits’ will become available in the future. If so, gene doping 
could become widely accessible to athletes regardless of 
their financial situation.
Those who reject conventional doping on ethical grounds 
will also reject gene doping. However, an acceptance of 
conventional doping, as advocated by a minority of bioethi-
cists, would rationally permit the full use of GM technology in 
sports. If this were to happen, then there can be little doubt 
that world sporting records (many of which have reached 
a plateau) would tumble, and athletic performance would 
reach hitherto unprecedented levels. As GM technology 
advances, athletes, regulatory bodies and society in general 
will need to decide whether to open the door to the ‘brave 
new world’ of gene doping.
Conclusions
Recent developments in molecular biotechnology have 
provided new approaches to the treatment of several 
diseases, but have also generated new opportunities for 
cheating in sports. Most recently, these discoveries have 
enabled the potential use of gene doping, a strategy that 
promises (or threatens) to radically enhance athletic per-
formance using GM approaches that will be hard to detect. 
Sport-regulatory organizations will need to remain vigilant 
for signs that gene doping starts to be used by athletes; 
if this does happen, scientists will need to rise to the 
challenge of entering an ‘arms race’ to develop effective 
means to detect such abuse. Meanwhile, bioethicists need 
to promote an active debate on an important emerging 
question: should gene doping be banned, controlled or 
liberalized?
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